Citadel Advisors
SPRY icon

Citadel Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Citadel Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.25M Sell
531,063
-1,242,125
-70% -$10.7M ﹤0.01% 5012
2026
Q1 		$14.2M Sell
1,773,188
-181,284
-9% -$1.74M ﹤0.01% 2753
2025
Q4 		$22.8M Buy
1,954,472
+368,439
+23% +$3.58M ﹤0.01% 2194
2025
Q3 		$15.9M Sell
1,586,033
-656,143
-29% -$9.42M ﹤0.01% 2614
2025
Q2 		$39.1M Buy
2,242,176
+1,440,886
+180% +$20.8M 0.01% 1440
2025
Q1 		$10.1M Sell
801,290
-4,166
-0.5% -$50.1K ﹤0.01% 2849
2024
Q4 		$8.5M Buy
805,456
+552,957
+219% +$7.74M ﹤0.01% 3194
2024
Q3 		$3.66M Buy
252,499
+161,741
+178% +$1.92M ﹤0.01% 4456
2024
Q2 		$772K Sell
90,758
-21,307
-19% -$189K ﹤0.01% 7125
2024
Q1 		$1.15M Buy
112,065
+80,262
+252% +$598K ﹤0.01% 6653
2023
Q4 		$174K Buy
31,803
+20,265
+176% +$88.8K ﹤0.01% 10150
2023
Q3 		$43.6K Sell
11,538
-208,810
-95% -$1.37M ﹤0.01% 11907
2023
Q2 		$1.48M Buy
220,348
+175,572
+392% +$1.17M ﹤0.01% 5708
2023
Q1 		$291K Buy
44,776
+36,479
+440% +$280K ﹤0.01% 9435
2022
Q4 		$70.8K Sell
8,297
-89,173
-91% -$579K ﹤0.01% 11688
2022
Q3 		$515K Sell
97,470
-134,196
-58% -$661K ﹤0.01% 8394
2022
Q2 		$982K Buy
231,666
+36,510
+19% +$127K ﹤0.01% 7058
2022
Q1 		$685K Buy
195,156
+101,591
+109% +$442K ﹤0.01% 8629
2021
Q4 		$623K Buy
93,565
+19,073
+26% +$155K ﹤0.01% 9130
2021
Q3 		$743K Buy
74,492
+39,844
+115% +$983K ﹤0.01% 8904
2021
Q2 		$1.07M Buy
+34,648
New +$1.11M ﹤0.01% 8207
2021
Q1 		– Sell
-138,138
Closed -$6.4M – 13684
2020
Q4 		$6.4M Buy
+138,138
New +$4.61M ﹤0.01% 3263

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors's SPRY Position: Q2 2026 in Review

Citadel Advisors reduced its ARS Pharmaceuticals (SPRY) stake by 70% in Q2 2026, selling an estimated $10.7M and leaving 531,063 shares worth $4.25M. The position accounts for ﹤0.01% of the portfolio, ranked #5012.

Citadel Advisors first reported a position in SPRY in Q4 2020 and has held it in 22 quarters since. The position peaked at $39.1M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Citadel Advisors held 531,063 shares of ARS Pharmaceuticals worth $4.25M as of Q2 2026.
  • Citadel Advisors sold 1,242,125 ARS Pharmaceuticals shares in Q2 2026, an estimated $10.7M.
  • ARS Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5012 holding.
  • Citadel Advisors first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Citadel Advisors's ARS Pharmaceuticals position peaked at $39.1M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.